Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01368211
Other study ID # CTS-0063
Secondary ID
Status Terminated
Phase Phase 2/Phase 3
First received June 6, 2011
Last updated February 27, 2014
Start date September 2010
Est. completion date May 2011

Study information

Verified date February 2014
Source Terumo BCTbio
Contact n/a
Is FDA regulated No
Health authority Denmark: Danish Medicines Agency
Study type Interventional

Clinical Trial Summary

The PRESS trial is a single-center, two-part, randomized cross-over pilot study in Copenhagen that will evaluate 1) the safety and performance of Mirasol-treated and untreated platelet products stored for 2-4 days and for 7-days in Platelet Additive Solution (PAS) and 2) the correlation between the TEG® parameters and platelet count increments after platelet transfusions in thrombocytopenic subjects.


Description:

1. To evaluate in thrombocytopenic subjects the efficacy and safety of platelets treated with Mirasol Pathogen Reduction Technology (PRT) in Platelet Additive Solution. The following safety and efficacy measures will be compared between Mirasol treated and untreated platelets stored for 2-4 days and stored for 7 days:

- Thrombelastography (TEG®) parameters: reaction time R, alpha angle α and maximal amplitude (MA)

- Platelet Count Increment and Corrected Count Increment

- Time to next platelet transfusion

- Incidence of transfusion related (serious) adverse events

- Incidence and severity of bleedings

2. To evaluate the use of the TEG® parameters as a measure for platelet transfusion efficacy and to evaluate the correlation between the TEG® parameters and the platelet Corrected Count Increments after platelet transfusions in thrombocytopenic subjects.


Recruitment information / eligibility

Status Terminated
Enrollment 16
Est. completion date May 2011
Est. primary completion date April 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female of age of 18 years or older.

- Have thrombocytopenia or expected to develop thrombocytopenia requiring at least 3 platelet transfusions.

- Woman of child bearing potential must have a negative serum or urine pregnancy test within 72 hours before randomization.

- Subjects must have signed and dated the Informed Consent Form before performing any protocol related procedure.

Exclusion Criteria:

- History of any hypersensitivity reaction to riboflavin or metabolites.

- History of refractoriness to platelet transfusions (defined as 2 successive CCI1hr<5000) or presence of human leukocyte antigen (HLA) antibodies or positive lymphocytotoxicity or previously documented alloimmunization.

- Previous exposure to PRT-treated platelet concentrates.

- Active bleeding requiring one or more red cells concentrate transfusions (i.e. grade 3 or 4 bleeding according to the WHO bleeding assessment scale in Appendix 1).

- Exposure to an investigational product, within 30 days before randomization.

- Splenomegaly (presence of a palpable spleen whose border could be felt more than 4 cm below the costal margin) or splenectomy.

- History or diagnosis of Immune/Idiopathic Thrombocytopenic Purpura (ITP), Thrombotic Thrombocytopenia Purpura (TTP), or Haemolytic Uremic Syndrome (HUS).

- Use of prohibited medication (see section 5.5).

- Pregnant or lactating females.

- Any medical condition or treatment that would be expected to compromise the effectiveness of a platelet transfusion or that would interfere with an expected platelet count increment.

- Any other medical condition that would compromise the participation of the subject in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Biological:
Mirasol-treated Platelets
Mirasol-treated platelet units with: Platelet yield between 2.4x10e11 and 4.5x10e11 Plasma carryover of >32% Cell count > 800x103/µL

Locations

Country Name City State
Denmark Hematology Service Rigshospitalet Copenhagen Blegdamsvej

Sponsors (1)

Lead Sponsor Collaborator
Terumo BCTbio

Country where clinical trial is conducted

Denmark, 

References & Publications (1)

Johansson PI, Simonsen AC, Brown PN, Ostrowski SR, Deberdt L, Van Hoydonck P, Yonemura SS, Goodrich RP. A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia. Transfusion. 2013 Sep;53(9):2043-52. d — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Maximum Amplitude at 1-hour Post-transfusion Thromboelastography (TEG) Parameter: Pre- to post-transfusional modification of Maximum Amplitude at 1-hour post-transfusion 1-hour post transfusion No
Secondary Change in Maximum Amplitude at 24-hours Post-transfusion Thromboelastography parameter: Pre- to post-transfusional modification in Maximum Amplitude at 24-hours post-transfusion 24 hour post transufusion No
See also
  Status Clinical Trial Phase
Recruiting NCT04003220 - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT03633019 - High-dose Use of rhTPO in CIT Patients Phase 4
Recruiting NCT06087198 - Clinical Performance Evaluation of T-TAS®01 HD Chip
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Active, not recruiting NCT03688191 - Study of Sirolimus in CTD-TP in China Phase 4
Completed NCT02845609 - Efficacy of Sialic Acid GNE Related Thrombocytopenia Phase 2
Recruiting NCT02241031 - Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia Phase 2/Phase 3
Recruiting NCT02244658 - Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia Phase 3
Unknown status NCT01196884 - Immune Thrombocytopenia (ITP) Immune-Genetic Assessment
Completed NCT01356576 - Effect of Hemodialysis Membranes on Platelet Count N/A
Completed NCT00039858 - Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Phase 4
Completed NCT00787241 - Platelet Count Trends in Pre-eclamptic Parturients N/A
Completed NCT00001533 - Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine Phase 1
Not yet recruiting NCT06036966 - The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients Phase 2
Completed NCT01791101 - Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia. Phase 2
Recruiting NCT06053021 - Antiplatelet Therapy for AIS Patients With Thrombocytopenia N/A
Recruiting NCT03701217 - Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML Phase 2/Phase 3
Not yet recruiting NCT05958511 - Assessment of Risk Factors and Outcome of Thrombocytopenia in ICU Patients
Completed NCT04917679 - Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP Phase 2